Acadia Pharma (ACAD) Halted Ahead of FDA PDAC Review of NUPLAZID

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced that NASDAQ has halted trading of the company’s common stock.

The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) is meeting today to review NUPLAZID (pimavanserin) for the treatment of patients with psychosis associated with Parkinson’s disease.

The Advisory Committee meeting is scheduled for 8:00 a.m. ET. The briefing materials can be found on the FDA website at http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/ucm475314.htm

You May Also Be Interested In

• Acadia Pharmaceuticals (ACAD) PT Raised to $49 at UBS
• Ionis to present olezarsen and ION775 data at ESC Congress 2026
• Gossamer Bio raises up to $250M in private placement for PAH drug